Ajay Major, MD, MBA
@majorajay.bsky.social
Lymphoma/CLL faculty at the University of Colorado School of Medicine. Patient-reported outcomes methodologist & #lymsm quality of life investigator. #medsky
Pinned
Happy #ASH25 day!
Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from this year's @ash.hematology.org meeting.
Check out the hashtag for details on all the abstracts: bsky.app/hashtag/Majo...
Check out all of this year's #MajorPROsASH, the top 20 best patient-reported outcomes & quality of life abstracts from this year's @ash.hematology.org meeting.
Check out the hashtag for details on all the abstracts: bsky.app/hashtag/Majo...
February 6, 2026 at 8:28 PM
Infx post CD20 bispecifics @bloodadvances.bsky.social
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...
February 3, 2026 at 3:36 PM
Infx post CD20 bispecifics @bloodadvances.bsky.social
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...
- 122 pts
- 61% ≥1 infx episode; 37% had Grade 3+ infx!!! (lots of CMV)
- 76% cumulative incidence infx at 2 yrs
- 8% G5 infx at 1 year
Important data (more infx than CAR?); need ppx/IVIG strategies. #lymsm
ashpublications.org/bloodadvance...
Hoping I have favor with the kiln deities! #pleasedontbreak #pottery
January 29, 2026 at 7:52 PM
Hoping I have favor with the kiln deities! #pleasedontbreak #pottery
Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @hms-mi.bsky.social consortium today! Be sure to read the full paper published @annalsofim.bsky.social: www.acpjournals.org/doi/10.7326/... #medsky #oncsky cc @davidpaje.bsky.social
January 29, 2026 at 7:07 PM
Elated to be presenting our MAGIC-ONC vascular access appropriateness recommendations in patients with cancer to the @hms-mi.bsky.social consortium today! Be sure to read the full paper published @annalsofim.bsky.social: www.acpjournals.org/doi/10.7326/... #medsky #oncsky cc @davidpaje.bsky.social
Q-TWIST analysis of CARTITUDE-4 @surbhisidanamd.bsky.social #ASH25: 9-13 month gain of quality-adjusted time w/o symptoms/toxicity as compared to SOC, and this includes time with high-grade ICANS. #mmsm #tcellrx
December 31, 2025 at 7:23 PM
Q-TWIST analysis of CARTITUDE-4 @surbhisidanamd.bsky.social #ASH25: 9-13 month gain of quality-adjusted time w/o symptoms/toxicity as compared to SOC, and this includes time with high-grade ICANS. #mmsm #tcellrx
Epidemiological data on NLPHL presented at the @ash.hematology.org #ASH25 Annual Meeting. Using a UK-based cancer registry, higher incidence of NLPHL in Black and Asian patients as compared to White patients. 5-year OS and relative survival of >90%. #lymsm #NLPHLsm
December 29, 2025 at 4:07 PM
Epidemiological data on NLPHL presented at the @ash.hematology.org #ASH25 Annual Meeting. Using a UK-based cancer registry, higher incidence of NLPHL in Black and Asian patients as compared to White patients. 5-year OS and relative survival of >90%. #lymsm #NLPHLsm
More time toxicity work from #ASH25: adults with ALL spent 25% of days over the first year physically interacting with the health care system. Tremendous potential to improve this with novel agents and/or hospital at home care delivery models. #leusm #AYAsm #timetox @ash.hematology.org
December 29, 2025 at 4:03 PM
More time toxicity work from #ASH25: adults with ALL spent 25% of days over the first year physically interacting with the health care system. Tremendous potential to improve this with novel agents and/or hospital at home care delivery models. #leusm #AYAsm #timetox @ash.hematology.org
Pirto v venetoclax in R/R WM #ASH25
- 91 pts: 64 VEN
- MV model:⬇️PFS w/ ven if TP53mut;⬇️MRR & PFS w/ pirto if CXCR4mut
- no diff in MRR or PFS between pirto & VEN
- transition from BTKi to VEN = 62% IgM rebound (didn't happen w/ pirto)
Genetic-based tx decisions in WM! #lymsm
- 91 pts: 64 VEN
- MV model:⬇️PFS w/ ven if TP53mut;⬇️MRR & PFS w/ pirto if CXCR4mut
- no diff in MRR or PFS between pirto & VEN
- transition from BTKi to VEN = 62% IgM rebound (didn't happen w/ pirto)
Genetic-based tx decisions in WM! #lymsm
December 24, 2025 at 8:38 PM
A time toxicity analysis of CAR-T in NHL by Trotier et al. from #ASH25 (using claims data) found a 1-year median of 52 contact days, very similar to our multicenter study. Very promising that we can use claims data to generate these time toxicity data. #lymsm cc @uduranimd.bsky.social
December 24, 2025 at 8:30 PM
A time toxicity analysis of CAR-T in NHL by Trotier et al. from #ASH25 (using claims data) found a 1-year median of 52 contact days, very similar to our multicenter study. Very promising that we can use claims data to generate these time toxicity data. #lymsm cc @uduranimd.bsky.social
In our study of real-world survival & time toxicity of CAR-T vs BsAb in R/R FL, we found that CAR-T resulted in superior PFS but more time toxicity, with no difference in OS.
Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm
www.vumedi.com/video/ash-20...
Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm
www.vumedi.com/video/ash-20...
ASH 2025 Insights: Comparison of Real-World Survival Outcomes and Time Toxicity of CAR T-Cell vs. Bispecific Antibody Therapies in R/R FL - A Multicenter Cohort From 15 US Academic Institutions
A video from Ajay Major (as part of 2025 ASH Annual Meeting Insights Hub), posted on Dec 23, 2025.
www.vumedi.com
December 23, 2025 at 11:41 PM
In our study of real-world survival & time toxicity of CAR-T vs BsAb in R/R FL, we found that CAR-T resulted in superior PFS but more time toxicity, with no difference in OS.
Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm
www.vumedi.com/video/ash-20...
Over first year, 51-64 physical healthcare contact days with CAR-T vs 36-38 with BsAb. #lymsm
www.vumedi.com/video/ash-20...
Reposted by Ajay Major, MD, MBA
CU Cancer Center member Ajay Major (@majorajay.bsky.social), MD, MBA, led a study of more than 25,000 long-term childhood cancer survivors, to learn more about their rates of colorectal cancer and what their doctors can do about it ⬇️
https://bit.ly/3MkDl2t
https://bit.ly/3MkDl2t
Why Childhood Cancer Survivors Are at Higher Risk of Colorectal Cancer — and What Their Doctors Can Do About It
Ajay Major's research found childhood cancer survivors got subsequent colorectal cancer at younger ages and had high colorectal cancer mortality rates.
news.cuanschutz.edu
December 15, 2025 at 11:27 PM
CU Cancer Center member Ajay Major (@majorajay.bsky.social), MD, MBA, led a study of more than 25,000 long-term childhood cancer survivors, to learn more about their rates of colorectal cancer and what their doctors can do about it ⬇️
https://bit.ly/3MkDl2t
https://bit.ly/3MkDl2t
At #ASH25, we presented our patient-reported time toxicity study in 120 pts w/ R/R FL & DLBCL on mosun, glofi & epcor. Mosun & glofi w/⬇️all-cause healthcare visits & hours spent on cancer-related care in past 30 days v epcor.
More details in this #thread. #lymsm
www.sciencedirect.com/science/arti...
More details in this #thread. #lymsm
www.sciencedirect.com/science/arti...
December 15, 2025 at 10:43 PM
At #ASH25, we presented our patient-reported time toxicity study in 120 pts w/ R/R FL & DLBCL on mosun, glofi & epcor. Mosun & glofi w/⬇️all-cause healthcare visits & hours spent on cancer-related care in past 30 days v epcor.
More details in this #thread. #lymsm
www.sciencedirect.com/science/arti...
More details in this #thread. #lymsm
www.sciencedirect.com/science/arti...
Announcing my #ASHNewsDaily Golden Globule award picks for @ash.hematology.org #ASH25! I gave my awards to the best (shocker) patient-reported outcomes abstracts, including quality of life studies from trials and in real-world practice. #MajorPROsASH ashpublications.org/ashnewsdaily...
December 10, 2025 at 8:27 PM
Announcing my #ASHNewsDaily Golden Globule award picks for @ash.hematology.org #ASH25! I gave my awards to the best (shocker) patient-reported outcomes abstracts, including quality of life studies from trials and in real-world practice. #MajorPROsASH ashpublications.org/ashnewsdaily...
Thanks for all the great memories, my #ASH25 friends! Stay in touch, and looking forward to seeing your new abstracts at #ASH26. cc @ash.hematology.org
December 9, 2025 at 7:18 PM
Thanks for all the great memories, my #ASH25 friends! Stay in touch, and looking forward to seeing your new abstracts at #ASH26. cc @ash.hematology.org
Our budding PRO researcher Dr. Hofmeister @cuinternalmed.bsky.social in the @cuhematology.bsky.social Major Lab presented her work on quality of life in CTCL at the @ash.hematology.org #ASH25 Annual Meeting.
Thread below with our study findings. 🧵 #lymsm
Thread below with our study findings. 🧵 #lymsm
December 8, 2025 at 9:58 PM
Our budding PRO researcher Dr. Hofmeister @cuinternalmed.bsky.social in the @cuhematology.bsky.social Major Lab presented her work on quality of life in CTCL at the @ash.hematology.org #ASH25 Annual Meeting.
Thread below with our study findings. 🧵 #lymsm
Thread below with our study findings. 🧵 #lymsm
The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ash.hematology.org
December 7, 2025 at 10:01 PM
The L-THORs (Lymphoma Translational Health Outcomes Researchers) assemble at #ASH25, presenting work in patient-reported outcomes and time toxicity! 🎉 #lymsm cc @ash.hematology.org
December 7, 2025 at 7:14 PM